Loading...
Bispecific therapeutic monoclonal antibodies are an emerging treatment option for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and multiple myeloma, offering immunotherapeutic efficacy via linkage of a tumor cell surface antigen and a redirected effector T cell. Investigators now report a multicenter, industry-sponsored, phase 1/2 trial of epcoritamab, which targets B-cell-expressing CD20 and T-cell CD3 antigens.
Patients with relapsed or refractory mature B-cell lymphomas received epcoritamab subcutaneously in a stepped-up dosing schedule intended to mitigate cytokine release syndrome (CRS). Treatment was given in 4-week cycles and dosed once weekly in cycles 1 to 2, biweekly in cycles 3 to 6, and once every 4 weeks from cycle 7 onw…